Taken together, these findings highlight the potential application of a novel treatment approach by using erastin combined with uL3 as an antiproliferative and antimetastatic strategy for resistant CRC cells devoid of p53 and expressing low levels of uL3 and high levels of SLC7A11. Here, SLC7A11 is linked to colorectal carcinoma.